Verve Therapeutics, Inc. Class Action Lawsuit - VERV

The filed complaint alleges that Verve Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants did not fully disclose the circumstances under which the Heart-1 Phase 1b clinical trial of VERVE-101, its investigational gene editing medicine, would be halted; (2) defendants overstated the potential benefits of its proprietary lipid nanoparticle delivery system; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

In order to be eligible to join the VERV class action lawsuit, you must have incurred a loss on shares of Verve Therapeutics purchased during the class period listed above.

If you suffered a loss in Verve Therapeutics during the relevant time frame or pursuant to the relevant offering(s), you have until October 28, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.